Oral Amyloid Oligomer Inhibition with ALZ-801: A Precision Medicine Approach for Early Alzheimer’s Disease
- Targeting amyloid oligomer formation through an oral small molecule mechanism, avoiding ARIA-related safety concerns observed with antibody approaches, delivering a safer, scalable treatment option for early AD patients, including highrisk APOE4 carriers
- Presenting clinical findings from Phase 2 and 3 studies, demonstrating beneficial cognitive and functional outcomes in early disease, supporting ALZ-801 as a potential first-in-class oral disease-modifying therapy
- Positioning ALZ-801 in the evolving AD treatment landscape, offering a differentiated therapeutic pathway for APOE4 carriers, expanding precision medicine opportunities while complementing or replacing antibody-based strategies